vs
Side-by-side financial comparison of Cheche Group Inc. (CCG) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
Cheche Group Inc. is the larger business by last-quarter revenue ($32.8M vs $18.7M, roughly 1.8× CytomX Therapeutics, Inc.). Cheche Group Inc. runs the higher net margin — 0.5% vs -0.8%, a 1.3% gap on every dollar of revenue.
Cheche Group Inc. is a leading automotive digital service provider headquartered in China. It offers integrated solutions including auto insurance intermediary services, smart auto after-sales support, and connected vehicle technology products, serving individual car owners, auto dealerships, and insurance partners across domestic and select Southeast Asian markets.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
CCG vs CTMX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $32.8M | $18.7M |
| Net Profit | $153.6K | $-154.0K |
| Gross Margin | 5.7% | — |
| Operating Margin | — | -6.9% |
| Net Margin | 0.5% | -0.8% |
| Revenue YoY | — | -25.7% |
| Net Profit YoY | — | 97.6% |
| EPS (diluted) | $0.00 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $32.8M | — | ||
| Q2 25 | $26.0M | $18.7M | ||
| Q1 25 | — | $50.9M | ||
| Q4 24 | $18.6M | $38.1M | ||
| Q3 24 | — | $33.4M | ||
| Q2 24 | $36.1M | $25.1M | ||
| Q1 24 | — | $41.5M | ||
| Q4 23 | — | $26.6M |
| Q1 26 | $153.6K | — | ||
| Q2 25 | $-492.4K | $-154.0K | ||
| Q1 25 | — | $23.5M | ||
| Q4 24 | $-196.7K | $18.9M | ||
| Q3 24 | — | $5.7M | ||
| Q2 24 | $-7.6M | $-6.5M | ||
| Q1 24 | — | $13.8M | ||
| Q4 23 | — | $837.0K |
| Q1 26 | 5.7% | — | ||
| Q2 25 | 4.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 4.3% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q1 26 | — | — | ||
| Q2 25 | -2.0% | -6.9% | ||
| Q1 25 | — | 44.4% | ||
| Q4 24 | -0.3% | 46.4% | ||
| Q3 24 | — | 12.3% | ||
| Q2 24 | -4.7% | -33.7% | ||
| Q1 24 | — | 28.1% | ||
| Q4 23 | — | -2.3% |
| Q1 26 | 0.5% | — | ||
| Q2 25 | -1.9% | -0.8% | ||
| Q1 25 | — | 46.2% | ||
| Q4 24 | -1.1% | 49.6% | ||
| Q3 24 | — | 17.2% | ||
| Q2 24 | -21.0% | -26.0% | ||
| Q1 24 | — | 33.3% | ||
| Q4 23 | — | 3.1% |
| Q1 26 | $0.00 | — | ||
| Q2 25 | $-0.01 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-0.00 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $20.0M | $49.0M |
| Total DebtLower is stronger | $193.3K | — |
| Stockholders' EquityBook value | — | $119.9M |
| Total Assets | $203.5M | $175.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $20.0M | — | ||
| Q2 25 | $23.1M | $49.0M | ||
| Q1 25 | — | $47.6M | ||
| Q4 24 | $21.1M | $38.1M | ||
| Q3 24 | — | $40.6M | ||
| Q2 24 | $28.2M | $43.2M | ||
| Q1 24 | — | $36.2M | ||
| Q4 23 | — | $17.2M |
| Q1 26 | $193.3K | — | ||
| Q2 25 | $690.0K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q1 26 | — | — | ||
| Q2 25 | $47.1M | $119.9M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | $49.1M | $-456.0K | ||
| Q3 24 | — | $-23.5M | ||
| Q2 24 | $48.6M | $-31.2M | ||
| Q1 24 | — | $-31.7M | ||
| Q4 23 | — | $-47.4M |
| Q1 26 | $203.5M | — | ||
| Q2 25 | $177.3M | $175.1M | ||
| Q1 25 | — | $98.5M | ||
| Q4 24 | $177.7M | $120.5M | ||
| Q3 24 | — | $139.0M | ||
| Q2 24 | $139.3M | $159.2M | ||
| Q1 24 | — | $184.7M | ||
| Q4 23 | — | $201.8M |
| Q1 26 | — | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-15.8M |
| Free Cash FlowOCF − Capex | — | $-15.8M |
| FCF MarginFCF / Revenue | — | -84.6% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q2 25 | $-44.7M | $-15.8M | ||
| Q1 25 | — | $-21.0M | ||
| Q4 24 | $-15.8M | $-19.9M | ||
| Q3 24 | — | $-20.7M | ||
| Q2 24 | $-1.0K | $-19.5M | ||
| Q1 24 | — | $-26.0M | ||
| Q4 23 | — | $-22.0M |
| Q1 26 | — | — | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | $-21.2M | ||
| Q4 24 | $-16.0M | $-20.0M | ||
| Q3 24 | — | $-20.7M | ||
| Q2 24 | $-1.1K | $-19.6M | ||
| Q1 24 | — | $-26.2M | ||
| Q4 23 | — | $-22.2M |
| Q1 26 | — | — | ||
| Q2 25 | — | -84.6% | ||
| Q1 25 | — | -41.6% | ||
| Q4 24 | -85.9% | -52.5% | ||
| Q3 24 | — | -62.1% | ||
| Q2 24 | -0.0% | -78.2% | ||
| Q1 24 | — | -63.1% | ||
| Q4 23 | — | -83.5% |
| Q1 26 | — | — | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | 1.2% | 0.2% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | 0.0% | 0.4% | ||
| Q1 24 | — | 0.3% | ||
| Q4 23 | — | 1.0% |
| Q1 26 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | — | -3.61× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -1.89× | ||
| Q4 23 | — | -26.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCG
Segment breakdown not available.
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
